Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata

WALTHAM, Mass. , Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB ) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA will be featured across late-breaking oral and poster presentations at the European Academy of Dermatology and Venereology ("EADV") Congress, taking place September 30 – October 3, 2026 in Vienna, Austria.

Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.

"Our late-breaking oral and poster presentations highlighting additional 36-week results as well as initial findings from the 16-week off-drug period from Part B of SIGNAL-AA underscores our commitment to bringing a differentiated, targeted therapeutic to patients with alopecia areata in need of new treatment options and the growing enthusiasm for bempikibart's unique mechanism in the field," said Jodie Morrison, Chief Executive Officer of Q32 Bio.

The oral presentation details are as follows:

Title: Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial

Abstract Number: LB-375

Session: D1T01.1 – Late Breaking News

Presenter: Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation, Brigham and Women's Hospital, Harvard Medical School

Date and Time: Wednesday, September 30, 2026, 3:15 p.m. CEST / 9:15 a.m. EST

Location: Hall A

The poster presentation details are as follows:

Title: Preliminary Results for an Open-label Phase 2a Trial (SIGNAL-AA Part B) of Bempikibart, a Novel IL-7Rα Antibody in Patients with Severe or Very Severe Alopecia Areata (AA)

Abstract Number: AS-726

Session: Biologics, immunotherapy, targeted therapy

Presenter: Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation, Brigham and Women's Hospital, Harvard Medical School

Date and Time: Wednesday, September 30, 2026, 7:00 a.m. CEST / 1:00 a.m. EST

Location: Poster Area

The presentations will be available in the " Presentations and Publications " section of the Q32 Bio website following the formal EADV presentation.

About Q32 Bio

Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases.

About 700,000 people in the United States live with alopecia areata 1 , a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. For more information, visit www.Q32Bio.com . 1 National Alopecia Areata Foundation Availability of Other Information About Q32 Bio Investors...